Search Results - Ukrainskyj, S.M

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS)

    CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) by Garcia-Manero, G, Savona, M.R, Gore, S.D, Scott, B.L, Cogle, C.R, Boyd, T, Conkling, P, Hetzer, J, Dong, Q, Kumar, K, Ukrainskyj, S.M, Skikne, B.S

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

    99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) by Garcia-Manero, G, Savona, M.R, Gore, S.D, Cogle, C.R, Conkling, P, Hetzer, J, Dong, Q, Ukrainskyj, S.M, Skikne, B.S

    Published in Leukemia research
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE

    60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLE... by Savona, M.R, Kolibaba, K, Conkling, P, Kingsley, E.C, Becerra, C, Morris, J.C, Rifkin, R.M, Laille, E, Kellerman, A, Ukrainskyj, S.M, Dong, Q, Skikne, B.S

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    25 - CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS)

    25 - CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) by Garcia-Manero, G., Savona, M.R., Gore, S.D., Scott, B.L., Cogle, C.R., Boyd, T., Conkling, P., Hetzer, J., Dong, Q., Kumar, K., Ukrainskyj, S.M., Skikne, B.S.

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: